Answers are grounded in this paper and cite their sources.
Randomized trial compares the efficacy and safety of CGRP monoclonal antibodies and oral gepants for migraine prevention, indicating significant findings.
To compare the efficacy and safety of calcitonin gene–related peptide (CGRP) monoclonal antibodies and oral gepants for migraine prevention using network meta-analysis with SUCRA-based ranking.
No takes yet. Share an insight, caveat, or question.
Anne et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: